Garweg J G, Wenzel A
Swiss Eye Institute, Berner Augenklinik am Lindenhofspital, Universität Bern, Bremgartenstrasse 119, 3012, Bern, Switzerland.
Ophthalmologe. 2010 Jul;107(7):628-35. doi: 10.1007/s00347-010-2176-x.
The incidence of diabetic microvascular complications is expected to increase by 20-50% in the coming years. Diabetic macular edema (DME) is already a leading cause of blindness in the working-age population in developed countries, and its impact is expected to increase dramatically.
Recent literature on the epidemiology and impact of diabetic microangiopathy (maculopathy) on visual function was reviewed to provide a comprehensive overview of the functional and socioeconomic consequences of diabetic retinal microangiopathy and new therapeutic strategies.
The first changes indicating diabetic microangiopathy are detectable shortly after the development of hyperglycemia, and in the long term they induce severe organ damage. More resources are used for this condition's treatment than for the treatment of hyperglycemia, corresponding to an enormous sociomedical burden of disease. Early detection of increased retinal vascular permeability may help control treatment effects. The control of recognized risk factors for the development and progression of DME, namely hyperglycemia and hyperlipidemia, as well as of hypertension has remained the cornerstone of therapy and serves as the basis for preserving visual function.
Modern treatment options, begun early, may result in a remarkably delayed occurrence of irreversible diabetic microvascular pathologies, particularly diabetic retinopathy and maculopathy. Ophthalmological screening nowadays aims at earlier recognition of at-risk individuals to optimize the therapeutic strategy--that is, before visual impairment is imminent. Close interdisciplinary medical cooperation and implementation of new therapeutic options may provide the foundation for success in terms of maintaining visual function.
预计在未来几年,糖尿病微血管并发症的发病率将增加20%-50%。糖尿病性黄斑水肿(DME)已是发达国家劳动年龄人口失明的主要原因,且其影响预计将大幅增加。
回顾了近期关于糖尿病微血管病变(黄斑病变)的流行病学及其对视觉功能影响的文献,以全面概述糖尿病视网膜微血管病变的功能和社会经济后果以及新的治疗策略。
在血糖升高后不久即可检测到表明糖尿病微血管病变的最初变化,从长期来看,这些变化会导致严重的器官损伤。用于治疗这种疾病的资源比用于治疗高血糖的资源更多,这相当于巨大的社会医疗疾病负担。早期检测视网膜血管通透性增加可能有助于控制治疗效果。控制已确认的DME发生和进展的危险因素,即高血糖、高血脂以及高血压,仍然是治疗的基石,也是保留视觉功能的基础。
早期开始的现代治疗方案可能会显著延迟不可逆糖尿病微血管病变的发生,尤其是糖尿病视网膜病变和黄斑病变。如今眼科筛查旨在更早识别高危个体,以优化治疗策略,即在视力损害即将发生之前。密切的跨学科医疗合作以及新治疗方案的实施可能为维持视觉功能的成功奠定基础。